Abstract
BackgroundThe aim of this study was to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) program in a Tertiary care hospital in Karachi, Pakistan.MethodologyThis study was conducted by interventional cardiology department of the National Institute of Cardiovascular Diseases (NICVD), Karachi from July 2015 to February 2020. All patients of severe aortic stenosis (AS) who underwent TAVI were included. Baseline characteristics, in-hospital course and one-month follow-up data were collected.ResultsThis study included 100 consecutive patients with severe AS undergoing TAVI. Sixty-three (63.0%) patients were males and the mean age was 67.38 ± 10.73 years. Eighty-five (85%) patients were in the New York Heart Association (NYHA) class III-IV. Aortic valve mean gradient was 51.33±10.47 mmHg and 50% of patients had bicuspid aortic valves. Core valve was implanted in 86 (86%) and evolute-R aortic valve was implanted in 14 (14%) patients. TAVI was successfully done in 94% of patients. Post-deployment aortic valve mean gradient was 5.33±4.13 mmHg. Major vascular access site complications were noted in 14% and atrioventricular (AV) blocks were seen in 22% of cases. There was a significant difference in symptoms of patients before and after the procedure. Overall, eight (8%) patients expired during hospital stay. At one-month follow-up, 76% of patients were found to have no limitation of physical activities.ConclusionsResults of this study showed that TAVI is a safe procedure in these high-risk patients and is an alternative to surgery for AS patients in the region.
Highlights
Aortic stenosis (AS) is the disease of the elderly and its prevalence increases with increasing age [1]
Eighty-five (85%) patients were in the New York Heart Association (NYHA) class III-IV
transcatheter aortic valve implantation (TAVI) was successfully done in 94% of patients
Summary
Aortic stenosis (AS) is the disease of the elderly and its prevalence increases with increasing age [1]. It is suggested that the valve area decreases by 0.1 cm per year [2]. The prognosis of untreated patients becomes poor. Surgical aortic valve replacement (SAVR) remained the gold standard in the treatment of severe AS patients [4]. Because of advanced age, frailty and comorbid conditions, many patients are considered high risk for SAVR. For such patients, for the first time, transcatheter aortic valve implantation (TAVI) was done in 2002 by Allen Crebier in France. Since TAVI became the treatment of choice for inoperable and high-risk severe AS patients [5]. The aim of this study was to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) program in a Tertiary care hospital in Karachi, Pakistan
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.